You have no items in your shopping cart.
ABSTRACT
The defining feature of asthma is chronic inflammation of the airways brought on by an excess of mast cells, activated T helper lymphocytes, and eosinophils. This study aimed to determine if asthma in asthma-induced Sprague-Dawley rats reduce or increase the lipid profile with treatment options of Montelukast and Prednisolone. The primary objective was to investigate how Montelukast and Prednisolone, two commonly prescribed medications for asthma management, impact lipid metabolism in the context of induced asthma. Sprague Dawley rats weighing between 180-250g were divided into four groups: Control, Negative Control and Asthma + Montelukast, and Asthma + Prednisolone. Asthma was induced through sensitization and all test groups (3 and 4) were sensitized with 1mg OVA and 200 mg aluminum hydroxide dissolved in 0.9 saline on day 0 and 7 and challenged with OVA (1 % w/v, adsorbed in 0.9 saline) twice weekly from day 7 of treatment until the last day. After confirmation of asthma in all test groups by evidence of neutrophilia and eosinophilia when compared to Control groups, treatment began with 3 mg/kg Prednisolone (oral) and 10 mg/kg Montelukast for four weeks. At the end of drug administration, all animals were euthanized and blood and tissue samples were collected for biomarker assay. Results showed a statistically significant decrease in both low density lipoprotein (LDL) and total cholesterol with p<0.05 in Montelukast when compared to Control and Negative control groups, while also showing a statistically significant increase in both Low Density Lipoprotein (LDL) and total cholesterol in Prednisolone compared to Montelukast and the Control group. In conclusion, this study demonstrated how Montelukast, primarily an anti-inflammatory, showed reduced effects on lipids while Prednisolone, also a potent anti-inflammatory and natural corticosteroid had negative effects on lipid profile with higher levels of its components.
